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According to the current (2015) recommenda-
tions of Global Initiative for Asthma (GINA) dealing 
under the auspice of World Health Organization 
(WHO) and in line with registered by EMA in EU 
as well as in Poland Summary of Product Charac-
teristics (SmPC) [1] Polish Society of Allergology 
considers, that there is a need of modification of 
inclusion criteria to Therapeutic Program for treat-
ment of severe IgE-mediated allergic asthma, which 
is a service guaranteed by National Health Found 
(NHF) (Table 1 presents the proposals of changes). 
Currently inclusion criteria are very restrictive, 
limiting access to the treatment for many groups of 
patients, especially children, who could benefit from 
biological treatment. Scientific evidence from clini-
cal [2] as well as observational [3] trials consistently 
show a significant advantage from early introduction 
of biological treatment in eligible patients before 
development of complications resulted from severe 
course of disease, including airflow limitation, life
-threatening exacerbations or adverse reactions after 
systemic therapy with corticosteroids (CS), among 
others hypertension, osteoporosis, cataract, glauco-
ma, metabolic syndrome and diabetes as well as 
growth inhibition and puberty disorders in children.
Hereby Polish Society of Allergology is requ-
esting as follow:
1. To decrease of age of eligible patients and 
covered by treatment in Therapeutic Program 
the children of age between 6 and 12 years, 
not only older than 12 years as currently. In-
dications for treatment in this age group exist 
since 2010, after extended drug registration 
based on the evidence of efficacy and safety 
in this group of patients. GINA experts also 
recommend the treatment with omalizumab 
in patients over 6 years of age [2].
2. To establish lower threshold for daily dose 
of inhaled corticosteroids (ICS) on the level 
of > 400 mcg/day (BDP-CFC) for children at 
the age between 6–12 years, according to the 
table of equivalent doses of ICS, developed by 
GINA experts, in which the doses > 400 mcg/
day in that age group are already considered 
as high (Box 3−6, pp 32) [1].
3. To remove criterion „Common previous using 
of oral CS (OCS), including past 6 months”, 
because there is no such a prerequisite for 
treatment with omalizumab neither in GINA 
recommendations [1] nor SmPC [2]. Moreo-
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ver, GINA experts prefer omalizumab as add-
-on-therapy to the grade 4 treatment rather 
than chronic administration of low doses of 
OCS [1]. According to the current Program, 
the prerequisite indicated by Program Coor-
dinating Committee is taking a minimum 
mean daily dose of OCS calculated from 
previous 6 months of 5 mg of equivalent dose 
of prednisone [5], which practically excludes 
patients without chronic administration of 
OCS. According to the GINA experts’ high- 
lights and clinical trials evidence, chronic 
administration of OCS, even in low do-
ses, constitutes a significant risk of serious 
adverse systemic reactions [1]. At the time 
being the aim of asthma therapy is not only 
current symptoms control, but minimizing 
of future risk, including the risk of therapy 
adverse reactions [1]. Hence, it seems to be 
appropriate to use primarily the treatment 
with possible lower risk of serious adverse 
reactions to save future suffer of patients and 
to decrease of cost resulted from treatment of 
complications.
4. To modify the recommendations regarding 
treatment of severe exacerbations. In their 
novel recommendation GINA experts highli-
ghted that short courses of OCS could be 
replaced by high doses ICS [1]1. Inhaled route 
of corticosteroids administration is always 
safer than oral, taking into consideration lo-
wer systemic exposure, leading to the lower 
risk of after-steroids complications. This is 
extremely important in group of patients 
susceptible for systemic CS, such as children 
and adolescent as well as diabetic patients, 
with metabolic syndrome, osteoporosis and 
other serious complications after CS therapy. 
If, according to the treating physician’s opi-
nion, there is more beneficial to use in the 
first line the nebulization with high doses of 
ICS in a patients due to high risk of steroids 
adverse reactions, this therapy should be 
accepted, as there is evidence of its clinical 
equivalence compare to OCS [6−9]. Accor-
ding to the suggestions of Polish Society of 
Allergology experts, nebulization with ICS 
dose of over 2000 mcg/day should be con-
sidered as clinically relevant. Additionally, 
one should remember about the patients who 
continuously take systemic CS in order to 
prevent the exacerbations. Chronic therapy 
with OCS is heavily burdened with the risk 
of adverse reactions. Introduction of biologi-
cal therapy for this group of patients gives a 
chance for limiting of demand of OCS, and 
sometimes even permanent discontinuation 
of that therapy [10−12].
5. To increase the spirometric threshold from 
< 60% of expected value < 80% of expec-
ted value or to the best personal value for 
the patients older than 12 years, and to not 
establish any spirometric criterion for chil-
dren between 6−12 years. This is in line in 
SmPC statement [2]. In the recent revision 
of their guidelines GINA experts removed 
the spirometric criterion from current asth-
ma control [1], therefore it is not taken into 
consideration during treatment schedule 
planning, and omalizumab itself has no 
bronchodilating effect and improvement of 
lung function is not an expected result of 
treatment. Decreasing of lung function below 
60% of expected value is a future high risk 
factor and is commonly observed in patients 
with long-lasting severe asthma, in which 
obstructive changes resulted from remode-
ling are irreversible. The aim of treatment of 
patients within Therapeutic Program should 
be prevention of such states rather than 
waiting for severe airway limitation, hence 
the increasing of threshold to < 80% as in 
SmPC seems to be justified.
6. To leave other criteria without any changes.
It should be clearly emphasized, that the 
introduction of Therapeutic Program of treat-
ment of severe IgE-mediated asthma in 2013 
and reimbursement from public sources was an 
indubitable success of Country Consultant for Al-
lergology, Polish Society of Allergology, covering 
allergologists and patients suffering from severe 
asthma, with their continuous efforts as well as 
Ministry of Health and National Health Found. 
This program enabled wider access to biological 
treatment for patients with severe asthma and 
moved Poland closer to the standards accepted in 
other UE countries. Each and every patient, who 
meets inclusion criteria can be treated within the 
program, without any restrictions of eligible pa-
tient’s’ number. Currently there are 372 patients 
within the program. Since the beginning of the 
Program only 40 patients were excluded from 
treatment due to lack of significant improvement 
or other reasons, which confirms the high clinical 
effectiveness of the drug [13]. Therefore, making 
available this treatment to the bigger group of 
patients with severe asthma could give a chan-
ce for better quality of life to bigger number of 
patients as well as their families, and it could 
limit the healthcare system burden connected to 
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the treatment of disease acute exacerbations and 
adverse reactions of therapy with CS. Estimated 
number of patients with severe asthma, eligible to 
immunological criteria according to the program 
Criteria is app. 1000 [14], so there is no expec-
tations of uncontrolled increasing of number 
of program’s participants after introduction of 
suggested changes. 
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Table 1. Summary of suggested by Polish Society of Allergology changes to the inclusion Criteria of Therapeutic Program 
of treatment of severe IgE-mediated asthma
Current Program inclusion criteria Suggested Program inclusion criteria Base of modi-
fication
1. Patients older than 12 years with severe, uncontrolled 
allergic asthma (according GINA 2009) with allergy to pe-
rennial aeroallergen, confirmed by SPT or sIgE
1. Patients older than 6 years with severe, uncontrolled 
allergic asthma (according GINA 2015) with allergy to pe-
rennial aeroallergen, confirmed by SPT or sIgE
SmPC
2. Demonstrating the clear reactivity in vitro (RAST) to 
perennial aeroallergen in patients with total IgE serum con-
centration below 76 IU/ml
2. Demonstrating the clear reactivity in vitro (RAST ELISA) 
to perennial aeroallergen in patients with total IgE serum 
concentration below 76 IU/ml
3. The need to administer high doses of ICS (> 1000 mcg 
BDP CFC/day) in combination with other asthma control-
ling drug (LABA, LTRA, theophylline derivatives)
3. The need to administer high doses of ICS (> 1000 mcg 
BDP CFC/day in adults and > 400 mcg/day in children 
6−12 years) in combination with other asthma controlling 
drug (LABA, LTRA, theophylline derivatives)
GINA
4. Common previous administration of oral CS, including 
last 6 months
4. Point removed GINA, SmPC
5. Meeting at least 3 following criteria: 5. Meeting at least 3 following criteria:
a) The symptoms of uncontrolled asthma (lack of asthma 
control in asthma control test ACQ > 1.5 points)
a) The symptoms of uncontrolled asthma (lack of asthma 
control in asthma control test ACQ > 1.5 points)
b) 3 or more episodes of exacerbations during the year, 
requiring administration of systemic CS or increasing the 
doses in patients using them permanently
b) 3 or more episodes of exacerbations during the year, 
requiring administration of systemic CS or high doses of 
CSI in nebulization >2000 mcg/day in equivalence to 
BUD or a need to continuous administer systemic CS 
(≥ 5 mg/day in in equivalence to prednisone) in order to 
prevent the exacerbations of disease
GINA
c) Hospitalization during previous 12 months due to exacer-
bation of asthma
c) Hospitalization during previous 12 months due to exacer-
bation of asthma
d) Previous life-threating asthma attack d) Previous life-threating asthma attack
e) Continuous airways obturation (forced expiratory volume 
in one second FEV1 < 60% of expected value or daily 
changes of peak expiratory flow PEF > 30%)
e) Continuous decreasing of lung function (FEV1 < 80% of 
expected value or the best value) in patients ≥ 12 years
SmPC
f) Asthma-related decreasing of quality of life (mean score 
in asthma quality of life control test AQLQ < 5.0 points)
f) Asthma-related decreasing of quality of life (mean score 
in asthma quality of life control test AQLQ < 5.0 points)
6. Total IgE serum concentration 30−1500 IU/ml 6. Total IgE serum concentration 30−1500 IU/ml 
7. Body mass 20−150 kg 7. Body mass 20−150 kg
8. Non-smoking 8. Non-smoking
9. Exclusion of underlined mechanisms (concomitant dise-
ases) leading to severe course of asthma other than body 
reaction on perennial aeroallergen
9. Exclusion of underlined mechanisms (concomitant dis-
eases) leading to severe course of asthma other than body 
reaction on perennial aeroallergen
CS – corticosteroid, ICS — inhaled corticosteroid, SmPC — Summary of Product Characteristics GINA— Global Initiative for Asthma; SPT — skin prick-testing; 
RAST — radioallergosorbent test; LABA — long acting beta agonist; LTRA — leukotriene receptor antagonists; ACQ — Asthma Control Questionnaire; FEV1 — forced 
expiratory volume in one second; AQLQ — Asthma Quality of Life Questionnaire
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